Emma Em Knowles1, Peter J Meikle2, Kevin Huynh2, Harald Hh Göring3, Rene L Olvera4, Samuel R Mathias1, Ravi Duggirala3, Laura Almasy5, John Blangero3, Joanne E Curran3, David C Glahn1,6. 1. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 2. Baker Heart and Diabetes Institute, Melbourne, Vic., Australia. 3. South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine, Brownsville, TX, USA. 4. Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 5. Department of Genetics, University of Pennsylvania and Department of Biomedical and Health Informatics at Children's Hospital of Philadelphia, PA, USA. 6. Olin Neuropsychiatric Research Center, Institute of Living, Hartford Hospital, Hartford, CT, USA.
Abstract
OBJECTIVES: Individuals with bipolar disorder (BPD) exhibit alterations in their phospholipid levels. It is unclear whether these alterations are a secondary consequence of illness state, or if phospholipids and illness risk overlap genetically. If the latter were true, then phospholipids might provide key insights into the pathophysiology of the illness. Therefore, we rank-ordered phospholipid classes by their genetic overlap with BPD risk in order to establish which class might be most informative in terms of increasing our understanding of illness pathophysiology. METHODS: Analyses were conducted in a sample of 558 individuals, unselected for BPD, from 38 extended pedigrees (average family size=14.79, range=2-82). We calculated a coefficient of relatedness for all family members of nine individuals with BPD in the sample (N=185); this coefficient was set to be zero in unrelated individuals (N=373). Then, under an endophenotype ranking value (ERV) approach, this scalar index was tested against 13 serum-based phospholipid concentrations in order to rank-order lipid classes by their respective overlap with BPD risk. RESULTS: The phosphatidylinositol class was significantly heritable (h2 =0.26, P=6.71 × 10-05 ). It was the top-ranked class, and was significantly associated with BPD risk after correction for multiple testing (β=-1.18, P=2.10 × 10-03 , ERV=0.49). CONCLUSIONS: We identified a peripheral biomarker, serum-based phosphatidylinositol, which exhibits a significant association with BPD risk. Therefore, given that phosphatidylinositol and BPD risk share partially common etiology, it seems that this lipid class warrants further investigation, not only in terms of treatment, but also as a promising diagnostic and risk marker.
OBJECTIVES: Individuals with bipolar disorder (BPD) exhibit alterations in their phospholipid levels. It is unclear whether these alterations are a secondary consequence of illness state, or if phospholipids and illness risk overlap genetically. If the latter were true, then phospholipids might provide key insights into the pathophysiology of the illness. Therefore, we rank-ordered phospholipid classes by their genetic overlap with BPD risk in order to establish which class might be most informative in terms of increasing our understanding of illness pathophysiology. METHODS: Analyses were conducted in a sample of 558 individuals, unselected for BPD, from 38 extended pedigrees (average family size=14.79, range=2-82). We calculated a coefficient of relatedness for all family members of nine individuals with BPD in the sample (N=185); this coefficient was set to be zero in unrelated individuals (N=373). Then, under an endophenotype ranking value (ERV) approach, this scalar index was tested against 13 serum-based phospholipid concentrations in order to rank-order lipid classes by their respective overlap with BPD risk. RESULTS: The phosphatidylinositol class was significantly heritable (h2 =0.26, P=6.71 × 10-05 ). It was the top-ranked class, and was significantly associated with BPD risk after correction for multiple testing (β=-1.18, P=2.10 × 10-03 , ERV=0.49). CONCLUSIONS: We identified a peripheral biomarker, serum-based phosphatidylinositol, which exhibits a significant association with BPD risk. Therefore, given that phosphatidylinositol and BPD risk share partially common etiology, it seems that this lipid class warrants further investigation, not only in terms of treatment, but also as a promising diagnostic and risk marker.
Authors: David C Glahn; Joanne E Curran; Anderson M Winkler; Melanie A Carless; Jack W Kent; Jac C Charlesworth; Matthew P Johnson; Harald H H Göring; Shelley A Cole; Thomas D Dyer; Eric K Moses; Rene L Olvera; Peter Kochunov; Ravi Duggirala; Peter T Fox; Laura Almasy; John Blangero Journal: Biol Psychiatry Date: 2011-10-07 Impact factor: 13.382
Authors: K N Fountoulakis; E Vieta; J Sanchez-Moreno; S G Kaprinis; J M Goikolea; G S Kaprinis Journal: J Affect Disord Date: 2005-05 Impact factor: 4.839
Authors: Peter J Meikle; Gerard Wong; Despina Tsorotes; Christopher K Barlow; Jacquelyn M Weir; Michael J Christopher; Gemma L MacIntosh; Benjamin Goudey; Linda Stern; Adam Kowalczyk; Izhak Haviv; Anthony J White; Anthony M Dart; Stephen J Duffy; Garry L Jennings; Bronwyn A Kingwell Journal: Arterioscler Thromb Vasc Biol Date: 2011-11 Impact factor: 8.311
Authors: Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer Journal: Lancet Neurol Date: 2015-04 Impact factor: 44.182
Authors: Ayşe Demirkan; Aaron Isaacs; Peter Ugocsai; Gerhard Liebisch; Maksim Struchalin; Igor Rudan; James F Wilson; Peter P Pramstaller; Ulf Gyllensten; Harry Campbell; Gerd Schmitz; Ben A Oostra; Cornelia M van Duijn Journal: J Psychiatr Res Date: 2012-11-30 Impact factor: 4.791
Authors: Josephine Mollon; Joanne E Curran; Samuel R Mathias; Emma E M Knowles; Phoebe Carlisle; Peter T Fox; Rene L Olvera; Harald H H Göring; Amanda Rodrigue; Laura Almasy; Ravi Duggirala; John Blangero; David C Glahn Journal: Diabetologia Date: 2020-02-04 Impact factor: 10.122
Authors: Emma E M Knowles; Joanne E Curran; Peter J Meikle; Kevin Huynh; Samuel R Mathias; Harald H H Göring; John L VandeBerg; Michael C Mahaney; Maria Jalbrzikowski; Marian K Mosior; Laura F Michael; Rene L Olvera; Ravi Duggirala; Laura Almasy; David C Glahn; John Blangero Journal: Neuropsychopharmacology Date: 2018-07-23 Impact factor: 7.853
Authors: Ole Kristian Drange; Olav Bjerkehagen Smeland; Alexey A Shadrin; Per Ivar Finseth; Aree Witoelar; Oleksandr Frei; Yunpeng Wang; Sahar Hassani; Srdjan Djurovic; Anders M Dale; Ole A Andreassen Journal: Front Neurosci Date: 2019-03-13 Impact factor: 4.677